- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
FibroGen Inc (FGEN)
FibroGen Inc stock price live, this page displays NASDAQ FGEN stock exchange data. View the FGEN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the FibroGen Inc real time stock price chart below.
What Is the FibroGen Inc Stock Price Today?
The FibroGen Inc stock price today is 7.450.
What Is the Stock Symbol for FibroGen Inc?
The stock symbol for FibroGen Inc is ""FGEN.""
What Stock Exchange Does FibroGen Inc Trade On?
FibroGen Inc is listed and trades on the NASDAQ stock exchange.
Is FibroGen Inc a Good Stock to Buy?
Determining whether FibroGen Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the FGEN quote. (ISIN: US31572Q8814)
What Is the FibroGen Inc Stock Price Today?
The FibroGen Inc stock price today is 7.450.
What Is the Stock Symbol for FibroGen Inc?
The stock symbol for FibroGen Inc is ""FGEN.""
What Stock Exchange Does FibroGen Inc Trade On?
FibroGen Inc is listed and trades on the NASDAQ stock exchange.
Is FibroGen Inc a Good Stock to Buy?
Determining whether FibroGen Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the FGEN quote. (ISIN: US31572Q8814)
7.450
+0.220(+3.04%)
Closed·
After Hours
7.4600.000(0.00%)
·
Fair Value
An estimate of a FibroGen Inc's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
7.041
7.560
52 wk Range
4.500
33.000
FGEN Scorecard
Full Analysis
Operates with a significant debt burden
FGEN is not included in our AI-picked strategies. See which stocks are.
Review Strategies
Fair Value
An estimate of a FibroGen Inc's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
7.0417.560
52 wk Range
4.50033.000
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
FGEN Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a FibroGen Inc's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Price Target
250.000
Upside
+3,255.70%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- Form 8K FibroGen Inc For: 14 July
- Investing.com
- Form 8K FibroGen Inc For: 14 July
- Investing.com
- FibroGen expands board with biotech veteran Kauffman
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Buy
Moving Averages
Strong Buy
FibroGen Inc Company Profile
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. Its pipeline products include FG-3165 and FG-3175, an anti-GAL-9 antibody for treatment of solid tumors. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
FibroGen Inc Earnings Call Summary for Q1/2025
- Q1 2025 revenue fell to $2.7M from $25.4M YoY; net loss reduced to $16.8M. Stock rose 2.13% to $0.312 in aftermarket trading.
- FibroGen China divestment to AstraZeneca expected to close Q3 2025, strengthening finances and extending cash runway to H2 2027.
- Phase II trial for FG3246 in prostate cancer set for Q3 2025. Seeking FDA feedback on Roxadustat for anemia treatment.
- 2025 revenue guidance: $4M-$8M. Operating costs down 76% YoY. R&D expenses reduced 75% YoY to $9.2M.
- Cash position: $128.4M total, $33.8M in US. Divestment proceeds to reduce debt and support operations.
Last Updated: 12/05/2025, 22:50
Read Full TranscriptCompare FGEN to Peers and Sector
Metrics to compare | FGEN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipFGENPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.2x | −5.2x | −0.5x | |
PEG Ratio | 0.00 | −0.19 | 0.00 | |
Price/Book | −0.1x | 3.0x | 2.6x | |
Price / LTM Sales | 4.3x | 11.1x | 3.2x | |
Upside (Analyst Target) | - | 110.2% | 40.5% | |
Fair Value Upside | Unlock | 15.7% | 4.4% | Unlock |
Analyst Ratings
1 Buy
1 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 250.000
(+3,255.70% Upside)
Earnings
Latest Release
May 13, 2025
EPS / Forecast
0.05 / -0.10
Revenue / Forecast
2.74M / 35.50M
People Also Watch
FAQ
What Stock Exchange Does FibroGen Inc Trade On?
FibroGen Inc is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for FibroGen Inc?
The stock symbol for FibroGen Inc is "FGEN."
What Is the FibroGen Inc Market Cap?
As of today, FibroGen Inc market cap is 30.09M.
What Is FibroGen Inc's Earnings Per Share (TTM)?
The FibroGen Inc EPS (TTM) is -30.04.
When Is the Next FibroGen Inc Earnings Date?
FibroGen Inc will release its next earnings report on 10 Aug 2025.
From a Technical Analysis Perspective, Is FGEN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has FibroGen Inc Stock Split?
FibroGen Inc has split 1 times.
How Many Employees Does FibroGen Inc Have?
FibroGen Inc has 225 employees.
What is the current trading status of FibroGen Inc (FGEN)?
As of 25 Jul 2025, FibroGen Inc (FGEN) is trading at a price of 7.45, with a previous close of 7.23. The stock has fluctuated within a day range of 7.04 to 7.56, while its 52-week range spans from 4.50 to 33.00.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.